News headlines about TrovaGene (NASDAQ:TROV) have trended somewhat positive recently, Accern Sentiment Analysis reports. The research group scores the sentiment of press coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. TrovaGene earned a news impact score of 0.09 on Accern’s scale. Accern also gave news articles about the medical research company an impact score of 45.7834985826868 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
TROV has been the subject of several recent research reports. Maxim Group set a $4.00 price target on TrovaGene and gave the company a “buy” rating in a report on Wednesday, October 18th. downgraded TrovaGene from a “buy” rating to a “hold” rating in a report on Wednesday, November 15th. Finally, HC Wainwright initiated coverage on TrovaGene in a report on Thursday, December 21st. They issued a “buy” rating and a $1.00 price target for the company. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have assigned a buy rating to the company. TrovaGene has a consensus rating of “Hold” and a consensus target price of $3.70.
Shares of TrovaGene (NASDAQ TROV) traded down $0.01 during midday trading on Friday, reaching $0.34. The company had a trading volume of 454,842 shares, compared to its average volume of 2,340,000. TrovaGene has a 52-week low of $0.23 and a 52-week high of $2.40. The firm has a market cap of $17.84, a P/E ratio of -0.34 and a beta of 0.40.
TrovaGene (NASDAQ:TROV) last announced its quarterly earnings results on Thursday, November 9th. The medical research company reported ($0.12) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.14) by $0.02. TrovaGene had a negative return on equity of 259.94% and a negative net margin of 7,960.05%. The firm had revenue of $0.12 million during the quarter. analysts predict that TrovaGene will post -0.78 EPS for the current year.
ILLEGAL ACTIVITY WARNING: “TrovaGene (TROV) Getting Somewhat Positive News Coverage, Analysis Finds” was first published by Transcript Daily and is the property of of Transcript Daily. If you are accessing this story on another website, it was illegally copied and reposted in violation of United States and international copyright law. The original version of this story can be viewed at https://transcriptdaily.com/2018/01/14/trovagene-trov-getting-somewhat-positive-news-coverage-analysis-finds.html.
Trovagene, Inc is a clinical-stage, precision medicine oncology therapeutics company. The Company’s lead drug candidate, PCM-075, is a Polo-like Kinase 1 (PLK1) selective adenosine triphosphate (ATP) competitive inhibitor. PCM-075 has shown preclinical antitumor activity as a single agent and in synergy combinations with more than ten different chemotherapeutics and targeted therapies, such as Zytiga (abiraterone acetate), Beleodaq (belinostat), Quizartinib (AC220), a development stage FLT3 inhibitor, and Velcade (bortezomib) in Acute Myeloid Leukemia (AML), metastatic Castration-Resistant Prostate Cancer (mCRPC) and other liquid and solid tumor cancers.
Receive News & Ratings for TrovaGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TrovaGene and related companies with MarketBeat.com's FREE daily email newsletter.